<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Bipolar Disord</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Bipolar Disord</journal-id>
<journal-title-group>
<journal-title>International Journal of Bipolar Disorders</journal-title>
</journal-title-group>
<issn pub-type="epub">2194-7511</issn>
<publisher>
<publisher-name>Springer Berlin Heidelberg</publisher-name>
<publisher-loc>Berlin/Heidelberg</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31814040</article-id>
<article-id pub-id-type="pmc">6900376</article-id>
<article-id pub-id-type="publisher-id">163</article-id>
<article-id pub-id-type="doi">10.1186/s40345-019-0163-y</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Study Protocols</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Investigating the relationship between melatonin levels, melatonin system, microbiota composition and bipolar disorder psychopathology across the different phases of the disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Manchia</surname>
<given-names>Mirko</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Squassina</surname>
<given-names>Alessio</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pisanu</surname>
<given-names>Claudia</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Congiu</surname>
<given-names>Donatella</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garzilli</surname>
<given-names>Mario</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guiso</surname>
<given-names>Beatrice</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Suprani</surname>
<given-names>Federico</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paribello</surname>
<given-names>Pasquale</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pulcinelli</surname>
<given-names>Vittoria</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Iaselli</surname>
<given-names>Maria Novella</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pinna</surname>
<given-names>Federica</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Valtorta</surname>
<given-names>Flavia</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Carpiniello</surname>
<given-names>Bernardo</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5686-7194</contrib-id>
<name>
<surname>Comai</surname>
<given-names>Stefano</given-names>
</name>
<address>
<email>comai.stefano@hsr.it</email>
</address>
<xref ref-type="aff" rid="Aff5">5</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1755 3242</institution-id><institution-id institution-id-type="GRID">grid.7763.5</institution-id><institution>Section of Psychiatry, Department of Medical Sciences and Public Health, </institution><institution>University of Cagliari, </institution></institution-wrap>Cagliari, Italy </aff>
<aff id="Aff2"><label>2</label>Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8200</institution-id><institution-id institution-id-type="GRID">grid.55602.34</institution-id><institution>Department of Pharmacology, </institution><institution>Dalhousie University, </institution></institution-wrap>Halifax, NS Canada </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1755 3242</institution-id><institution-id institution-id-type="GRID">grid.7763.5</institution-id><institution>Department of Biomedical Science, Section of Neuroscience and Clinical Pharmacology, </institution><institution>University of Cagliari, </institution></institution-wrap>Cagliari, Italy </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000000417581884</institution-id><institution-id institution-id-type="GRID">grid.18887.3e</institution-id><institution>San Raffaele Scientific Institute and Vita Salute University, </institution></institution-wrap>Via Olgettina 58, 20132 Milan, Italy </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8649</institution-id><institution-id institution-id-type="GRID">grid.14709.3b</institution-id><institution>Department of Psychiatry, </institution><institution>McGill University, </institution></institution-wrap>Montreal, QC Canada </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>9</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>9</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>7</volume>
<elocation-id>27</elocation-id>
<history>
<date date-type="received">
<day>7</day>
<month>8</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>10</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p id="Par1">Bipolar disorder (BD) is characterized by recurrent episodes of depression and mania/hypomania alternating with intervals of well-being. The neurobiological underpinnings of BD are still veiled although there is evidence pointing to a malfunction of the circadian clock system that is regulated by the neuromodulator melatonin (MLT). Small sample size studies in BD patients have shown that changes in the levels of MLT are associated with shifts in illness status. Moreover, mood stabilizers (including lithium and valproic acid) influence the MLT system. Of interest, MLT also modulates intestinal microbiota, and recent work suggests an important role of microbiota alterations in neuropsychiatric disorders, including BD. This study is designed to explore whether the possible patterns of associations between changes in the levels of MLT and its precursors and BD mood phases are modulated by variants within the genes encoding for the elements of the MLT system and/or by the microbiota composition.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">We will conduct a 2-year follow-up study in 50 BD patients during the three different mood phases of the disease. For each phase, we will perform a blood withdrawal for the analysis of MLT levels and of variants of the genes related to the MLT pathway between 8 and 10 a.m. after an overnight fasting, a stool specimen collection for the analysis of microbiota composition, and a detailed psychometric assessment for depression, mania, impulsivity and cognitive abilities. We will also recruit 50 healthy age-matched controls in whom we will perform a blood withdrawal between 8 and 10 a.m. after an overnight fasting, a stool specimen collection, and a psychometric assessment to exclude the presence of psychiatric disorders.</p>
</sec>
<sec>
<title>Discussion</title>
<p id="Par3">In this cross sectional (case–control vs. BD comparisons) and longitudinal (24 months) study, we expect to clarify the link between the MLT system, microbiota and BD psychopathology. We expect to identify some typical BD symptomatic clusters that will be more strictly associated with variations in the MLT system. In a personalized medicine perspective, this subgroup of BD patients may benefit from a pharmacological therapy targeting the MLT system.</p>
<p id="Par4"><italic>Trial registration</italic> This study protocol was approved by the Ethics Committee of the University Hospital Agency of Cagliari (PG/2019/6277)</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Melatonin</kwd>
<kwd>Bipolar disorder</kwd>
<kwd>Genetic variability</kwd>
<kwd>Microbiota</kwd>
<kwd>Observational study</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000874</institution-id>
<institution>Brain and Behavior Research Foundation</institution>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par5">Bipolar disorder (BD) is a complex chronic psychiatric condition characterized by recurrent episodes of depression and mania/hypomania alternating with intervals of well-being. According to the World Health Organization, BD is among the top 10 leading cause of years lived with disability (Murray and Lopez <xref ref-type="bibr" rid="CR35">1996</xref>). Epidemiological estimates show that 1–5% of people across all populations suffers from diverse types of BD (Angst et al. <xref ref-type="bibr" rid="CR1">2003</xref>). Further, BD carries a high burden in terms of treatment costs (Dilsaver <xref ref-type="bibr" rid="CR9">2011</xref>), effect on families and careers, loss of productivity and increased mortality (Lomholt et al. <xref ref-type="bibr" rid="CR31">2019</xref>). Patients with BD experience substantial residual morbidity resulting in up to 50% of follow-up time spent ill, mainly in depression (Joffe et al. <xref ref-type="bibr" rid="CR26">2004</xref>; Post et al. <xref ref-type="bibr" rid="CR40">2003</xref>), with a risk of relapse at 5 years that remains high (about 70%) even in the presence of maintenance treatment (Gitlin et al. <xref ref-type="bibr" rid="CR16">1995</xref>). Selecting the most effective therapy for a BD patient thus still remains a challenge for clinicians (Geddes and Miklowitz <xref ref-type="bibr" rid="CR15">2013</xref>) and despite progress in the study of the neurobiology and psychopharmacology of the disease, options remain limited and results are often unsatisfactory. Thus, more research is needed to better understand the neurobiology of the disease and to discover and validate novel potential targets for drug development.</p>
<p id="Par6">A key component of BD psychopathology (i.e. illness cyclicity) appears to correspond to a neurobiological malfunction of the circadian clock system (Dallaspezia and Benedetti <xref ref-type="bibr" rid="CR6">2009</xref>, <xref ref-type="bibr" rid="CR7">2015</xref>) that is regulated by the suprachiasmatic nucleus (SCN). Patients affected by BD show alterations of intrinsic biological rhythms, including the sleep–wake cycle, as well as of hormonal rhythms and of the regulation of body temperature (Harvey <xref ref-type="bibr" rid="CR24">2008</xref>). A key neurochemical modulator of the circadian clock system is melatonin (MLT). This neuromodulator derives from serotonin (5-HT) and is mainly synthesized in the pineal gland during the night. The physiological effects of MLT are mostly mediated by two high-affinity G-protein coupled receptors (GPCRs), MT<sub>1</sub> and MT<sub>2</sub> (Dubocovich et al. <xref ref-type="bibr" rid="CR11">2010</xref>; Jockers et al. <xref ref-type="bibr" rid="CR25">2016</xref>). MLT is one of the endogenous entraining signals for the circadian system, regulating the activity of the SCN that expresses both MT<sub>1</sub> and MT<sub>2</sub> receptors (Dubocovich et al. <xref ref-type="bibr" rid="CR11">2010</xref>; Jockers et al. <xref ref-type="bibr" rid="CR25">2016</xref>). However, the exact mechanism/s through which MLT regulates the SNC is still to be clarified. Indeed, in vitro and in vivo studies have reported contrasting findings (Dubocovich and Markowska <xref ref-type="bibr" rid="CR10">2005</xref>) [for details on this topic, please see our recent papers (Gobbi and Comai <xref ref-type="bibr" rid="CR17">2019a</xref>, <xref ref-type="bibr" rid="CR18">b</xref>)]. The MLT system seems to be a potential target system for the treatment of mood disorders since agomelatine, a non-selective agonist for both MT<sub>1</sub> and MT<sub>2</sub> receptors and an antagonist for 5-HT<sub>2C</sub> receptors has entered clinical use for the treatment of major depression (de Bodinat et al. <xref ref-type="bibr" rid="CR8">2010</xref>).</p>
<p id="Par7">Given the link between MLT and the circadian rhythms, and between the latter and BD (McCarthy <xref ref-type="bibr" rid="CR33">2019</xref>; Gonzalez et al. <xref ref-type="bibr" rid="CR19">2018</xref>), a series of seminal studies have investigated and demonstrated changes in the levels of MLT associated with illness status in patients with BD (Kennedy et al. <xref ref-type="bibr" rid="CR29">1996</xref>; Lam et al. <xref ref-type="bibr" rid="CR30">1990</xref>; Nurnberger et al. <xref ref-type="bibr" rid="CR37">2000</xref>). In particular, affected subjects have low serum levels of MLT than healthy controls (trait marker) (Kennedy et al. <xref ref-type="bibr" rid="CR29">1996</xref>). However, Whalley et al. (<xref ref-type="bibr" rid="CR44">1991</xref>) did not replicate this finding. Although there is no apparent variation in the MLT levels in relation to a specific phase of the disease (Kennedy et al. <xref ref-type="bibr" rid="CR29">1996</xref>), the peak of MLT at night is delayed in euthymic BD patients (Nurnberger et al. <xref ref-type="bibr" rid="CR37">2000</xref>). In addition, Nurnberger et al. (<xref ref-type="bibr" rid="CR37">2000</xref>) showed higher light-induced suppression of MLT in BD patients than in controls, whereas, in contrast, Lam et al. (<xref ref-type="bibr" rid="CR30">1990</xref>) reported greater light-induced suppression of MLT in controls than in BD patients. Whalley et al. (<xref ref-type="bibr" rid="CR44">1991</xref>) instead did not find any significant difference in the effect of light on MLT comparing healthy individuals and BD patients (Whalley et al. <xref ref-type="bibr" rid="CR44">1991</xref>). Therefore, the presence of a MLT supersensitivity to light as a reliable trait marker of BD needs to be clarified. Overall, the small size of the population analyzed strongly limits the validity of the currently available studies.</p>
<p id="Par8">In addition to a possible link between dysfunctional MLT levels and BD pathophysiology, there is also a strong hint for a modulating effect of treatments for BD on MLT levels and function. Indeed, in healthy volunteers the mood stabilizer valproic acid significantly decreased the sensitivity of MLT to light (Hallam et al. <xref ref-type="bibr" rid="CR21">2005</xref>). Further, in a study in Long Evans rats, lithium significantly influenced MLT levels in several brain regions along the retinal-hypothalamic-pineal pathway (Seggie et al. <xref ref-type="bibr" rid="CR41">1987</xref>).</p>
<p id="Par9">Another biological component, non-genetic but heritable to some extent, that could impact brain function is the gut microbiota. There is growing evidence that the bidirectional signalling along the gut-brain axis may play an important role in the pathophysiology of depression, anxiety and autism spectrum disorder (ASD) (Foster and McVey Neufeld <xref ref-type="bibr" rid="CR14">2013</xref>; Sharon et al. <xref ref-type="bibr" rid="CR42">2019</xref>; Zheng et al. <xref ref-type="bibr" rid="CR48">2016</xref>). Relevant to our project is the evidence that microbiota alterations could modulate the risk of BD, although findings are still preliminary (Nguyen et al. <xref ref-type="bibr" rid="CR36">2018</xref>; Pisanu and Squassina <xref ref-type="bibr" rid="CR39">2018</xref>). For instance, a diminished representation of Faecalibacterium and of an as yet unclassified member of the Ruminococcaceae family has been detected in subjects with BD with respect to controls (Evans et al. <xref ref-type="bibr" rid="CR12">2017</xref>). Interestingly, BD patients with higher levels of Faecalibacterium displayed better sleep quality and less severe depressive symptoms (Evans et al. <xref ref-type="bibr" rid="CR12">2017</xref>).</p>
<p id="Par10">The gut is the main organ involved in peripheral synthesis of MLT, and MLT and its precursor tryptophan exert an important regulatory role on the gastro-intestinal (GI) functions (Bubenik <xref ref-type="bibr" rid="CR4">2002</xref>). Indeed, altered tryptophan metabolism in the gut can lead to increased GI permeability, which in turn has been associated with psychiatric disorders (Kelly et al. <xref ref-type="bibr" rid="CR28">2015</xref>). MLT, when administered in mice subjected to a high-fat diet (HFD), reduces body weight, hepatic steatosis, low-grade systemic inflammation, improves insulin resistance, and significantly modifies the composition of the intestinal microbiota (Xu et al. <xref ref-type="bibr" rid="CR45">2017</xref>). A recent study indicates that MLT improves lipid metabolism in mice with a HFD diet probably through reprogramming of the microbiota (Yin et al. <xref ref-type="bibr" rid="CR46">2018</xref>). These still limited and recent findings highlight the importance of the intestinal microbiota in mediating the various physiological functions of MLT.</p>
<p id="Par11">Collectively, this evidence suggests a potential involvement of MLT and of the MLT system in the physiopathology of BD. The present study protocol is designed to explore in a sample of BD patients the possible link between the MLT system, microbiota and psychopathology across the different mood phases of the illness. In particular, we aim at exploring whether the patterns of associations identified between the levels of MLT and its precursors [tryptophan (Trp), 5-hydroxytryptophan (5-HTP), and 5-HT)] and BD mood phases are modulated by variants within the genes encoding for the elements of the MLT system, including MLT receptors and the enzymes involved in the synthesis and metabolism of MLT, and the microbiota composition.</p>
</sec>
<sec id="Sec2">
<title>Methods/design</title>
<sec id="Sec3">
<title>Recruiting procedures</title>
<p id="Par12">We will perform a 2-year follow-up study in 50 patients affected by BD and in 50 healthy controls of the same age group. Based on the existing data on the natural history of BD and our clinical experience, we estimate that 2 years should be sufficient to evaluate recurrences in BD patients who tend to have cycles of illness that last more than 1 year. A prospective follow-up with an in person psychiatric assessment and administration of psychometric scales will be done every month up to 24 months. In addition, weekly telephone assessments will be performed to detect eventual mood fluctuations. During the three different mood phases of the disease, BD patients will undergo, between 8 and 10 a.m. after an overnight fasting, a blood withdrawal, a stool specimen collection, and a detailed psychometric assessment for depression, mania, impulsivity and cognitive abilities. Further, recruited patients will undergo a medical examination to exclude the presence of severe unregulated medical conditions, such as for instance cardiovascular or metabolic diseases. Similarly, between 8 and 10 a.m. after an overnight fasting, control subjects will undergo a clinical assessment to exclude the presence of psychiatric disorders, a medical examination to exclude eventual severe unregulated medical conditions such as cardiovascular or metabolic diseases, a blood withdrawal and a stool specimen collection.</p>
</sec>
<sec id="Sec4">
<title>Diagnostic criteria</title>
<p id="Par13">The clinical diagnosis of BD will be formulated using the Italian version of the Structured Clinical Interview for DSM 5 (SCID-5) (First et al. <xref ref-type="bibr" rid="CR13">2017</xref>).</p>
<sec id="Sec5">
<title>Inclusion criteria for BD patients</title>
<p>
<list list-type="bullet"><list-item><p id="Par14">Diagnosis of BD type 1 or type 2 according to the DSM-5 criteria;</p></list-item><list-item><p id="Par15">Age between 18 and 65 years old.</p></list-item></list>
</p>
</sec>
<sec id="Sec6">
<title>Exclusion criteria</title>
<p>
<list list-type="bullet"><list-item><p id="Par16">Women in the fertile age, who do not use adequate contraception or who are pregnant;</p></list-item><list-item><p id="Par17">Past history of traumatic brain insults;</p></list-item><list-item><p id="Par18">Diagnosis of current and/or lifetime other psychiatric or neurological disorders or other severe unregulated medical conditions;</p></list-item><list-item><p id="Par19">Diagnosis of current and/or lifetime substance use disorder;</p></list-item><list-item><p id="Par20">Treatment with melatonergic compounds (melatonin and/or agomelatine) for at least 2 months before enrollment. Other treatments (beta blockers, benzodiazepines, low dose antipsychotics) will be allowed.</p></list-item></list>
</p>
</sec>
<sec id="Sec7">
<title>Inclusion criteria for controls</title>
<p>
<list list-type="bullet"><list-item><p id="Par21">Absence of psychiatric disorders diagnosed according to the DSM-5;</p></list-item><list-item><p id="Par22">Age between 18 and 65 years old;</p></list-item><list-item><p id="Par23">Absence of psychiatric, neurological or other severe unregulated medical conditions.</p></list-item></list>
</p>
</sec>
</sec>
<sec id="Sec8">
<title>Psychometric evaluations</title>
<p id="Par24">We will perform at each time point an extensive psychometric evaluation using the following validated scales: the Italian version of the Hamilton Depression Rating Scale 21-items (Hamilton <xref ref-type="bibr" rid="CR23">1960</xref>), the Italian version of the Hamilton Anxiety Rating Scale 21-item (Hamilton <xref ref-type="bibr" rid="CR22">1959</xref>), the Italian version of the Young Mania Rating Scale (YMRS) (Young et al. <xref ref-type="bibr" rid="CR47">1978</xref>); the Italian version of the Brief Assessment of Cognition in Affective Disorder (Keefe et al. <xref ref-type="bibr" rid="CR27">2014</xref>), the Italian version of the Clinical Global Index of Severity and a measure of the quality of life (WHOQOL-BREF) (Guy <xref ref-type="bibr" rid="CR20">1976</xref>), and the Italian version of the Barratt Impulsiveness Scale version-11 (Barratt <xref ref-type="bibr" rid="CR2">1985</xref>).</p>
</sec>
<sec id="Sec9">
<title>Sampling procedures</title>
<p id="Par25">Blood samples will be collected in BD patients in the three different mood phases of the disease (euthymia, depression and hypomania/mania) with a withdrawal performed from 8:00 a.m. to 10:00 a.m. after an overnight fasting. Three 10 mL aliquots (one for the analysis of the plasma levels of MLT and its precursors and two for genetic analyses) will be collected in EDTA containing tubes and immediately centrifuged at 2500 rpm at 4 °C for 10 min.</p>
</sec>
<sec id="Sec10">
<title>Analysis of the plasma levels of MLT and its precursors</title>
<p id="Par26">The analysis of plasma levels of MLT and its metabolites will be conducted according to our previously validated method (Longatti et al. <xref ref-type="bibr" rid="CR32">2007</xref>; Messaoud et al. <xref ref-type="bibr" rid="CR34">2018</xref>) by using an HPLC system (Varian Inc) provided with a Shimadzu RF-10AXL fluorimetric detector. The chromatographic separation is performed at room temperature using a Synergi Fusion-RP 80A column (4 μm; 250 mm × 4.6 mm; Phenomenex, Aschaffenburg, Germany). The mobile phase consists of acetonitrile/phosphate buffer (0.004 M, pH 3.5) in isocratic elution (15:85 v/v) and with a flow rate of 0.9 ml/min. The fluorimetric detector is placed at the excitation and emission wavelengths of 285 and 345 nm, respectively. Plasma samples are diluted 1:10 before the chromatographic analysis. The determinations will be conducted in triplicate for each sample analyzed.</p>
</sec>
<sec id="Sec11">
<title>Genetic analysis</title>
<p id="Par27">Genetic analysis will be performed with the Infinium PsychArray-24 BeadChip 1.2 (Illumina, San Diego, California, USA). This chip allows the evaluation of the genetic variants associated with the most common psychiatric disorders and includes 271,000 polymorphisms of the Infinium Core-24 BeadChip, 277,000 markers of the Infinium Exome-24 BeadChip, and 50,000 additional markers associated with common psychiatric disorders. Furthermore, the Infinium PsychArray-24 + v1.2 enables to add up to 60,000 additional markers, which in our study will be dedicated to the genes involved in the MLT pathway. The following genes related to the MLT pathway will be studied: MT<sub>1</sub> receptor (<italic>MTNR1A</italic>); MT<sub>2</sub> receptor (<italic>MTNR1B</italic>); tryptophan hydroxylase 1; tryptophan hydroxylase 2; acetylserotonin <italic>O</italic>-methyltransferase; aralkylamine <italic>N</italic>-acetyltransferase; retinoid-related orphan nuclear receptor alpha; retinoid-related orphan nuclear receptor beta; calmodulin 1; calmodulin 2; calmodulin 3; serotonin transporter (SLC6A4); catechol <italic>O</italic>-methyltransferase; monoamine oxidase A. Quality control and association analyses for the PsychArray will be carried out using PLINK v. 1.9 (Chang et al. <xref ref-type="bibr" rid="CR5">2015</xref>) applying stringent filtering criteria based on call rate, minor allele frequency, Hardy–Weinberg Disequilibrium, subject call rate. Considering the complexity of the study design and the large number of tests, only variants showing significance after correction for multiple testing in the comparison of patients versus controls will be carried forward in the next steps of the study. These significant variants will be included in regression models to test their effect on the clinical and molecular variables.</p>
</sec>
<sec id="Sec12">
<title>Microbiota analysis</title>
<p id="Par28">Microbial DNA will be isolated from the fecal material and then the 16S rRNA gene will be amplified. The analysis is completed by sequencing the regions V3 and V4 of the 16S rRNA gene pool corresponding to the microorganisms contained in the microbiota and then by their recognition with the use of bioinformatics tools (Metagenomics Illumina Inc. and Kraken APP). Analysis of the data generated on the Miseq System will be carried out using the BaseSpace 16 S Metagenomics App (Illumina), whereas operational taxonomic unit (OTU) mapping to the Greengenes database will be performed using the Quantitative Insights Into Microbial Ecology (QIIME) platform. Sequences containing ambiguous or low-quality bases will be filtered out using QIIME filter. Remaining sequences will be assigned to each sample according to the unique barcodes. Alpha diversity will be estimated using Shannon index metric.</p>
</sec>
<sec id="Sec13">
<title>Statistical analysis</title>
<p id="Par29">Differences in plasma levels of MLT and its precursors among the different disease stages will be tested by using repeated measures ANOVA, followed by the Tukey post hoc correction. The Kruskal–Wallis or Friedman test will be used in case data are not normally distributed. We will also compare the levels of MLT and its precursors between BD patients and controls by using t-test or Mann–Whitney U test, depending on the empirical data distribution. We will use regression analyses in order to evaluate the association between levels of MLT and its precursors and the measures of psychopathological severity. Regarding the microbiota analysis for quantitative variables, the indexes of position, dispersion and shape will be measured, while for the categorical ones, frequency of each individual class will be calculated. Data will be analyzed by using packages implemented in the Bioconductor suite in R. Regarding genetic analysis, we will use the chi-square, logistic regression and linear regression tests in order to evaluate the genetic associations, focusing especially on genes encoding elements of the MLT system. All these analyses will be performed using PLINK v. 1.9 (Chang et al. <xref ref-type="bibr" rid="CR5">2015</xref>) and R v. 3.6.1 (Team <xref ref-type="bibr" rid="CR43">2014</xref>). Each one of the tests performed in every analytical category will be corrected for multiple comparisons depending on the design of the test. However, considering the exploratory nature of this study, statistical significance after correction will not constitute a limitation for the identification and selection of molecular signatures for future investigations.</p>
</sec>
<sec id="Sec14">
<title>Analysis of the statistical power and sample size</title>
<p id="Par30">Previous estimates (Kennedy et al. <xref ref-type="bibr" rid="CR29">1996</xref>) have quantified the magnitude of the effect size of the statistically significant difference in MLT levels between healthy controls and BD patients that was 5.29. Considering this effect size, the analysis of statistical power performed with G*Power program (version 3.1.) established that a sample of 50 BD patients and 50 controls has more than 95% of the statistical power to identify a difference between groups, with an α set at 0.05. According to previous estimates of effect sizes for microbiota analyses (Painold et al. <xref ref-type="bibr" rid="CR38">2019</xref>), this sample size should be sufficient to achieve more than 90% of statistical power to detect a difference between groups, even accounting for an attrition rate of 10% during the follow-up with the same α.</p>
</sec>
<sec id="Sec15">
<title>Ethical issues and permission</title>
<p id="Par31">The study will be conducted in accordance with the recommendations adopted by the 18th World Medical Assembly, Helsinki 1964 and subsequent revisions. Informed consent will be obtained from the patient prior to the enrollment in the study. This study protocol was approved by the Ethics Committee of the University Hospital Agency of Cagliari (PG/2019/6277) on May 8, 2019. All data collected during the study procedures will be processed in accordance with the current regulations for the protection of privacy (regulation (EU) 2016/679 of the European parliament and of the council of 27 April 2016 (General Data Protection Regulation). In order to ensure the confidentiality of the data collected and blood samples, each patient will be given an identification code (a progressive number starting from 1 to 200 followed by the acronym “CA”) so that in no case there will the possibility of identifying the recruited subject. A psychiatric assessment establishes that patients’ ability to consent is not compromised by their psychopathological status.</p>
</sec>
</sec>
<sec id="Sec16">
<title>Discussion</title>
<p id="Par32">This study protocol is composed of two approaches: (1) a cross sectional part that will test whether differences in MLT levels are associated with illness status in BD patients (case–control comparison), and (2) a longitudinal prospective analysis lasting 24 months in which recruited patients will be monitored for the manifestations of mood episodes. Clinical measures and biological material will be collected at baseline in euthymia and when a significant mood disruption will be observed (case-only analysis). In both approaches we will test whether genetic and microbiota variation can modulate the identified associations. Using this approach, we expect to find a significant difference in the plasma levels of MLT and/or some of its precursors between healthy controls and BD patients, and also differences in these biomarkers in BD patients depending on the phase of the disease (depression versus hypomania/mania versus euthymia). Importantly, we also expect to find genetic alterations, in particular in those genes coding for elements of the MLT system, modulating the longitudinal association between the MLT plasma levels and the disease morbidity in BD patients. Very likely, we will identify some typical BD symptomatic clusters that will be more strictly associated with variations in the MLT system. These data could suggest that this group of patients could benefit from pharmacological treatment acting on the MLT system. Furthermore, another important expected result will be the identification of specific microbiota clusters associated with the peripheral variations of MLT, also in relation to the BD disease phase. The combination of extensive phenotypic information with omics data can lead to the discovery of novel, potentially clinically relevant associations, especially when adequate data mining techniques are applied (Breuer et al. <xref ref-type="bibr" rid="CR3">2018</xref>).</p>
<p id="Par33">The study design (cross-sectional in the comparison between controls and BD), however, will not allow us to establish a causality, i.e. if the altered MLT levels precede the development of BD. Therefore, although BD patients will be followed-up longitudinally, this study can be only considered as a proof-of-concept, and thus as a hypothesis generator and identifier of the size of the association between the variables under exam. In spite of these limitations, this study should be able to analyze, in depth and at different levels, the role of the MLT system (MLT and its precursors’ levels and the genetic variability) and its correlation with the microbiota composition in BD pathophysiology. Another limitation may arise by the fact that we will not study the entire 24-h secretion pattern of MLT and the possible variation in its precursors (e.g. by measuring their levels at different time points during the day and the night or measuring the 24-h excretion of 6-sulphatoxymelatonin in the urine) in relationships with the different biological and psychometric markers.</p>
<p id="Par34">Collectively, these data will help us to better clarify the neurobiology of BD and will be helpful for future projects aimed at the development of new drugs that, by targeting the MLT system, could help improving some of the symptoms of BD. It is important to remember that, to date, there are several pharmacological treatments for BD, but the rate of recurrence of the disease and the toxicity of these drugs are significant. Therefore, there is a great scientific and clinical interest in the development of new drugs, a process for which it is first necessary to better understand the neurobiology of BD.</p>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>
<bold>Publisher's Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
<fn>
<p>Mirko Manchia and Alessio Squassina equally contributed to the manuscript</p>
</fn>
<fn>
<p>Bernardo Carpiniello and Stefano Comai share senior authorship</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>MM and SC conceived the idea of this study, MM, AS, CP, FV, BC, SC contributed to the design of the study, including providing advice on the study protocol or components of the intervention. MM, AS, CP, SC prepared the first draft of the manuscript. MM, AS, CP, DC, MG, BG, FS, PP, VP, MNI, FP, FV, BC, SC are responsible for implementing the study. All authors (MM, AS, CP, DC, MG, BG, FS, PP, VP, MNI, FP, FV, BC, SC) contributed to editing the manuscript. All authors read and approved the final manuscript.</p>
</notes>
<notes notes-type="funding-information">
<title>Funding</title>
<p>This study is supported in part by a 2017 NARSAD Young Investigator Grant from the Brain and Behavior Research Foundation to SC. CP is supported by a fellowship funded by Fondazione Umberto Veronesi.</p>
</notes>
<notes notes-type="data-availability">
<title>Availability of data and materials</title>
<p>The datasets that will be collected during the current study will be available from the corresponding author on reasonable request.</p>
</notes>
<notes>
<title>Ethics approval and consent to participate</title>
<p id="Par35">This study protocol was approved by the Ethics Committee of the University Hospital Agency of Cagliari (PG/2019/6277) on May 8, 2019. Informed consent will be obtained from the patient prior to the enrollment in the study.</p>
</notes>
<notes>
<title>Consent for publication</title>
<p id="Par36">The document does not contain personal data, and consent for publication is not applicable.</p>
</notes>
<notes notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par37">The authors declare that they have no competing interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angst</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gamma</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Benazzi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ajdacic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Eich</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rössler</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania</article-title>
<source/>J Affect Disord
          <year>2003</year>
<volume>73</volume>
<issue>1</issue>
<fpage>133</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-0327(02)00322-1</pub-id>
<pub-id pub-id-type="pmid">12507746</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Barratt</surname>
<given-names>ES</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Spence</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Izard</surname>
<given-names>CE</given-names>
</name>
</person-group>
<article-title>Impulsiveness subtraits: arousal and information processing</article-title>
<source/>Motivation, emotion, and personality
          <year>1985</year>
<publisher-loc>New York</publisher-loc>
<publisher-name>Elsevier Science Publishers</publisher-name>
<fpage>137</fpage>
<lpage>46</lpage>
</element-citation>
</ref>
<ref id="CR3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breuer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mattheisen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Krumm</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Treutlein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kassem</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Detecting significant genotype-phenotype association rules in bipolar disorder: market research meets complex genetics</article-title>
<source/>Int J Bipolar Disord.
          <year>2018</year>
<volume>6</volume>
<issue>1</issue>
<fpage>24</fpage>
<pub-id pub-id-type="doi">10.1186/s40345-018-0132-x</pub-id>
<pub-id pub-id-type="pmid">30415424</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bubenik</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Gastrointestinal melatonin: localization, function, and clinical relevance</article-title>
<source/>Dig Dis Sci
          <year>2002</year>
<volume>47</volume>
<issue>10</issue>
<fpage>2336</fpage>
<lpage>2348</lpage>
<pub-id pub-id-type="doi">10.1023/A:1020107915919</pub-id>
<pub-id pub-id-type="pmid">12395907</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Tellier</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Vattikuti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Purcell</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JJJG</given-names>
</name>
</person-group>
<article-title>Second-generation PLINK: rising to the challenge of larger and richer datasets</article-title>
<source/>Gigasci
          <year>2015</year>
<volume>4</volume>
<issue>1</issue>
<fpage>7</fpage>
<pub-id pub-id-type="doi">10.1186/s13742-015-0047-8</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dallaspezia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Benedetti</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Melatonin, circadian rhythms, and the clock genes in bipolar disorder</article-title>
<source/>Curr Psychiatry Rep.
          <year>2009</year>
<volume>11</volume>
<issue>6</issue>
<fpage>488</fpage>
<lpage>493</lpage>
<pub-id pub-id-type="doi">10.1007/s11920-009-0074-1</pub-id>
<pub-id pub-id-type="pmid">19909672</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dallaspezia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Benedetti</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Chronobiology of bipolar disorder: therapeutic implication</article-title>
<source/>Curr Psychiatry Rep.
          <year>2015</year>
<volume>17</volume>
<issue>8</issue>
<fpage>606</fpage>
<pub-id pub-id-type="doi">10.1007/s11920-015-0606-9</pub-id>
<pub-id pub-id-type="pmid">26112914</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Bodinat</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Guardiola-Lemaitre</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Mocaer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Renard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Munoz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Millan</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Agomelatine, the first melatonergic antidepressant: discovery, characterization and development (vol 9, pg 628, 2010)</article-title>
<source/>Nat Rev Drug Discov.
          <year>2010</year>
<volume>9</volume>
<issue>9</issue>
<fpage>743</fpage>
<pub-id pub-id-type="doi">10.1038/nrd3274</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dilsaver</surname>
<given-names>SC</given-names>
</name>
</person-group>
<article-title>An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009</article-title>
<source/>J Affect Disord
          <year>2011</year>
<volume>129</volume>
<issue>1</issue>
<fpage>79</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2010.08.030</pub-id>
<pub-id pub-id-type="pmid">20888048</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubocovich</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Markowska</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Functional MT1 and MT2 melatonin receptors in mammals</article-title>
<source/>Endocrine
          <year>2005</year>
<volume>27</volume>
<issue>2</issue>
<fpage>101</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1385/ENDO:27:2:101</pub-id>
<pub-id pub-id-type="pmid">16217123</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubocovich</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Delagrange</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Sugden</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cardinali</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Olcese</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>International Union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors</article-title>
<source/>Pharmacol Rev.
          <year>2010</year>
<volume>62</volume>
<issue>3</issue>
<fpage>343</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="doi">10.1124/pr.110.002832</pub-id>
<pub-id pub-id-type="pmid">20605968</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Bassis</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Hein</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Assari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Flowers</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>MB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The gut microbiome composition associates with bipolar disorder and illness severity</article-title>
<source/>J Psychiatr Res
          <year>2017</year>
<volume>87</volume>
<fpage>23</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2016.12.007</pub-id>
<pub-id pub-id-type="pmid">27988330</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<mixed-citation publication-type="other">First M, Williams J, Karg R, Spitzer R. SCID-5-CV. Intervista Clinica Strutturata per i Disturbi del DSM-5. Versione Per Il Clinico Ed Italiana a cura Di Andrea Fossati e Serena Borroni: Raffaello Cortina Editore Milano; 2017.</mixed-citation>
</ref>
<ref id="CR14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foster</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>McVey Neufeld</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Gut-brain axis: how the microbiome influences anxiety and depression</article-title>
<source/>Trends Neurosci
          <year>2013</year>
<volume>36</volume>
<issue>5</issue>
<fpage>305</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2013.01.005</pub-id>
<pub-id pub-id-type="pmid">23384445</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geddes</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Miklowitz</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Treatment of bipolar disorder</article-title>
<source/>Lancet.
          <year>2013</year>
<volume>381</volume>
<issue>9878</issue>
<fpage>1672</fpage>
<lpage>1682</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(13)60857-0</pub-id>
<pub-id pub-id-type="pmid">23663953</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gitlin</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Swendsen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Heller</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Hammen</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Relapse and impairment in bipolar disorder</article-title>
<source/>Am J Psychiatry
          <year>1995</year>
<volume>152</volume>
<issue>11</issue>
<fpage>1635</fpage>
<pub-id pub-id-type="doi">10.1176/ajp.152.11.1635</pub-id>
<pub-id pub-id-type="pmid">7485627</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gobbi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Comai</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Differential function of melatonin MT1 and MT2 receptors in REM and NREM sleep</article-title>
<source/>Front Endocrinol.
          <year>2019</year>
<volume>10</volume>
<fpage>87</fpage>
<pub-id pub-id-type="doi">10.3389/fendo.2019.00087</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gobbi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Comai</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Sleep well. Untangling the role of melatonin MT1 and MT2 receptors in sleep</article-title>
<source/>J Pineal Res.
          <year>2019</year>
<volume>66</volume>
<issue>3</issue>
<fpage>e12544</fpage>
<pub-id pub-id-type="doi">10.1111/jpi.12544</pub-id>
<pub-id pub-id-type="pmid">30586215</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Suppes</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zeitzer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McClung</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tamminga</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tohen</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The association between mood state and chronobiological characteristics in bipolar I disorder: a naturalistic, variable cluster analysis-based study</article-title>
<source/>Int J Bipolar Disord.
          <year>2018</year>
<volume>6</volume>
<issue>1</issue>
<fpage>5</fpage>
<pub-id pub-id-type="doi">10.1186/s40345-017-0113-5</pub-id>
<pub-id pub-id-type="pmid">29457195</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Guy</surname>
<given-names>W</given-names>
</name>
</person-group>
<source/>ECDEU assessment manual for psychopharmacology: 1976
          <year>1976</year>
<publisher-loc>Bethesda</publisher-loc>
<publisher-name>National Institute of Mental Health</publisher-name>
</element-citation>
</ref>
<ref id="CR21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hallam</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Olver</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Norman</surname>
<given-names>TR</given-names>
</name>
</person-group>
<article-title>Effect of sodium valproate on nocturnal melatonin sensitivity to light in healthy volunteers</article-title>
<source/>Neuropsychopharmacology.
          <year>2005</year>
<volume>30</volume>
<issue>7</issue>
<fpage>1400</fpage>
<lpage>1404</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1300739</pub-id>
<pub-id pub-id-type="pmid">15841104</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamilton</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The assessment of anxiety states by rating</article-title>
<source/>Br J Med Psychol
          <year>1959</year>
<volume>32</volume>
<issue>1</issue>
<fpage>50</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1111/j.2044-8341.1959.tb00467.x</pub-id>
<pub-id pub-id-type="pmid">13638508</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamilton</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>A rating scale for depression</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>1960</year>
<volume>23</volume>
<fpage>56</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.23.1.56</pub-id>
<pub-id pub-id-type="pmid">14399272</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harvey</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation</article-title>
<source/>Am J Psychiatry
          <year>2008</year>
<volume>165</volume>
<issue>7</issue>
<fpage>820</fpage>
<lpage>829</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2008.08010098</pub-id>
<pub-id pub-id-type="pmid">18519522</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jockers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Delagrange</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dubocovich</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Markus</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Renault</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tosini</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Update on melatonin receptors: iUPHAR Review 20</article-title>
<source/>Br J Pharmacol
          <year>2016</year>
<volume>173</volume>
<issue>18</issue>
<fpage>2702</fpage>
<lpage>2725</lpage>
<pub-id pub-id-type="doi">10.1111/bph.13536</pub-id>
<pub-id pub-id-type="pmid">27314810</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joffe</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>MacQueen</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Marriott</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Trevor</surname>
<given-names>Young L</given-names>
</name>
</person-group>
<article-title>A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders</article-title>
<source/>Bipolar Disord
          <year>2004</year>
<volume>6</volume>
<issue>1</issue>
<fpage>62</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1046/j.1399-5618.2003.00091.x</pub-id>
<pub-id pub-id-type="pmid">14996142</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keefe</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Kennel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Burdick</surname>
<given-names>KE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Brief Assessment of Cognition In Affective Disorders (BAC-A):performance of patients with bipolar depression and healthy controls</article-title>
<source/>J Affect Disord
          <year>2014</year>
<volume>166</volume>
<fpage>86</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2014.05.002</pub-id>
<pub-id pub-id-type="pmid">25012414</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelly</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hyland</surname>
<given-names>NP</given-names>
</name>
</person-group>
<article-title>Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders</article-title>
<source/>Front Cell Neurosci.
          <year>2015</year>
<volume>9</volume>
<fpage>392</fpage>
<pub-id pub-id-type="pmid">26528128</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kennedy</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Kutcher</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Ralevski</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder</article-title>
<source/>Psychiatry Res
          <year>1996</year>
<volume>63</volume>
<issue>2–3</issue>
<fpage>219</fpage>
<lpage>222</lpage>
<pub-id pub-id-type="doi">10.1016/0165-1781(96)02910-1</pub-id>
<pub-id pub-id-type="pmid">8878318</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lam</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Berkowitz</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Berga</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Kripke</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Gillin</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Melatonin suppression in bipolar and unipolar mood disorders</article-title>
<source/>Psychiatry Res
          <year>1990</year>
<volume>33</volume>
<issue>2</issue>
<fpage>129</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1016/0165-1781(90)90066-E</pub-id>
<pub-id pub-id-type="pmid">2243889</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lomholt</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>DV</given-names>
</name>
<name>
<surname>Sejrsgaard-Jacobsen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ozdemir</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Graff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schjerning</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mortality rate trends in patients diagnosed with schizophrenia or bipolar disorder: a nationwide study with 20 years of follow-up</article-title>
<source/>Int J Bipolar Disord.
          <year>2019</year>
<volume>7</volume>
<issue>1</issue>
<fpage>6</fpage>
<pub-id pub-id-type="doi">10.1186/s40345-018-0140-x</pub-id>
<pub-id pub-id-type="pmid">30820700</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Longatti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Perin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rizzo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Comai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Giusti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>CV</given-names>
</name>
</person-group>
<article-title>Ventricular cerebrospinal fluid melatonin concentrations investigated with an endoscopic technique</article-title>
<source/>J Pineal Res
          <year>2007</year>
<volume>42</volume>
<issue>2</issue>
<fpage>113</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-079X.2006.00391.x</pub-id>
<pub-id pub-id-type="pmid">17286741</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCarthy</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Missing a beat: assessment of circadian rhythm abnormalities in bipolar disorder in the genomic era</article-title>
<source/>Psychiatr Genet
          <year>2019</year>
<volume>29</volume>
<issue>2</issue>
<fpage>29</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="doi">10.1097/YPG.0000000000000215</pub-id>
<pub-id pub-id-type="pmid">30516584</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messaoud</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mensi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Douki</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Neffati</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Najjar</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Gobbi</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced peripheral availability of tryptophan and increased activation of the kynurenine pathway and cortisol correlate with major depression and suicide</article-title>
<source/>World J Biol Psychiatry.
          <year>2018</year>
<pub-id pub-id-type="doi">10.1080/15622975.2018.1468031</pub-id>
<pub-id pub-id-type="pmid">29683396</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Murray</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>AD</given-names>
</name>
</person-group>
<source/>Global burden of disease
          <year>1996</year>
<publisher-loc>Cambridge</publisher-loc>
<publisher-name>Harvard University Press</publisher-name>
</element-citation>
</ref>
<ref id="CR36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Kosciolek</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Eyler</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jeste</surname>
<given-names>DV</given-names>
</name>
</person-group>
<article-title>Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder</article-title>
<source/>J Psychiatr Res
          <year>2018</year>
<volume>99</volume>
<fpage>50</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2018.01.013</pub-id>
<pub-id pub-id-type="pmid">29407287</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nurnberger</surname>
<given-names>JI</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Adkins</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lahiri</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Mayeda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lewy</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Melatonin suppression by light in euthymic bipolar and unipolar patients</article-title>
<source/>Arch Gen Psychiatry
          <year>2000</year>
<volume>57</volume>
<issue>6</issue>
<fpage>572</fpage>
<lpage>579</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.57.6.572</pub-id>
<pub-id pub-id-type="pmid">10839335</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Painold</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Morkl</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kashofer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Halwachs</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dalkner</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bengesser</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A step ahead: exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode</article-title>
<source/>Bipolar Disord
          <year>2019</year>
<volume>21</volume>
<issue>1</issue>
<fpage>40</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1111/bdi.12682</pub-id>
<pub-id pub-id-type="pmid">30051546</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pisanu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Squassina</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>We are not alone in our body: insights into the involvement of microbiota in the etiopathogenesis and pharmacology of mental illness</article-title>
<source/>Curr Drug Metab
          <year>2018</year>
<volume>19</volume>
<issue>8</issue>
<fpage>688</fpage>
<lpage>694</lpage>
<pub-id pub-id-type="doi">10.2174/1389200219666171227204144</pub-id>
<pub-id pub-id-type="pmid">29283065</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Post</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Denicoff</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Leverich</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Altshuler</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Suppes</surname>
<given-names>TM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method</article-title>
<source/>J Clin Psychiatry.
          <year>2003</year>
<volume>64</volume>
<issue>6</issue>
<fpage>680</fpage>
<lpage>690</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.v64n0610</pub-id>
<pub-id pub-id-type="pmid">12823083</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seggie</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Werstiuk</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Grota</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Lithium and circadian patterns of melatonin in the retina, hypothalamus, pineal and serum</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
          <year>1987</year>
<volume>11</volume>
<issue>2–3</issue>
<fpage>325</fpage>
<lpage>334</lpage>
<pub-id pub-id-type="doi">10.1016/0278-5846(87)90077-7</pub-id>
<pub-id pub-id-type="pmid">2819953</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharon</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cruz</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Gandal</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice</article-title>
<source/>Cell
          <year>2019</year>
<volume>177</volume>
<issue>6</issue>
<fpage>1600-18.e17</fpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2019.05.004</pub-id>
<pub-id pub-id-type="pmid">31150625</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>Team RCJU</collab>
</person-group>
<source/>A language and environment for statistical computing
          <year>2014</year>
<publisher-loc>R Foundation for Statistical Computing</publisher-loc>
<publisher-name>Vienna</publisher-name>
<fpage>2014</fpage>
</element-citation>
</ref>
<ref id="CR44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whalley</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Perini</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shering</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bennie</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Melatonin response to bright light in recovered, drug-free, bipolar patients</article-title>
<source/>Psychiatry Res
          <year>1991</year>
<volume>38</volume>
<issue>1</issue>
<fpage>13</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1016/0165-1781(91)90048-T</pub-id>
<pub-id pub-id-type="pmid">1658841</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Melatonin prevents obesity through modulation of gut microbiota in mice</article-title>
<source/>J Pineal Res.
          <year>2017</year>
<volume>62</volume>
<issue>4</issue>
<fpage>e12399</fpage>
<pub-id pub-id-type="doi">10.1111/jpi.12399</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Melatonin reprogramming of gut microbiota improves lipid dysmetabolism in high-fat diet-fed mice</article-title>
<source/>J Pineal Res
          <year>2018</year>
<volume>65</volume>
<issue>4</issue>
<fpage>e12524</fpage>
<pub-id pub-id-type="doi">10.1111/jpi.12524</pub-id>
<pub-id pub-id-type="pmid">30230594</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Biggs</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>A rating scale for mania: reliability, validity and sensitivity</article-title>
<source/>Br J Psychiatry
          <year>1978</year>
<volume>133</volume>
<issue>5</issue>
<fpage>429</fpage>
<lpage>435</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.133.5.429</pub-id>
<pub-id pub-id-type="pmid">728692</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism</article-title>
<source/>Mol Psychiatry.
          <year>2016</year>
<volume>21</volume>
<issue>6</issue>
<fpage>786</fpage>
<lpage>796</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2016.44</pub-id>
<pub-id pub-id-type="pmid">27067014</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>